We depict a potential origin for high IL-1β in human AML, and a type of patient that may be particularly good responder to anti-IL-1β therapies over patients that present with high IL-1β resulting from primary lesions in the signaling pathway downstream of IL-1R1. The gene discussed is IL1R1; the disease is acute myeloid leukemia.